Swedish biotech company AlzeCure Pharma AB (Nasdaq First North Premier Growth Market:ALZCUR) reported on Tuesday that the European Medicines Agency (EMA) has granted orphan drug designation to ACD440 for treatment of erythromelalgia, a rare chronic pain disorder with no approved therapies.
ACD440, the company's lead pain candidate within the Painless platform, previously completed a positive Phase IIa study in chronic peripheral neuropathic pain and received US orphan designation and FDA positive guidance in 2025 supporting continued Phase II/III development toward regulatory approval.
ACD440 is a first-in-class TRPV1 antagonist being developed as a topical gel to deliver high local analgesic effect with minimal systemic exposure. The compound originated in large pharmaceutical research and is based on Nobel Prize-recognised science from 2021.
Erythromelalgia affects just over 13 per 100,000 people and is characterised by severe burning pain, redness, swelling, and heat, primarily in the extremities such as the feet, hands, ears and nose.
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
StimLabs launches DermaForm collagen scaffold particulate device
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lupin's Amifampridine Tablets approved by US FDA
Roche wins FDA clearance for customisable respiratory pathogen test
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Immunome secures EMA validation of varegacestat application for desmoid tumors
FDA approves Sun Pharma's ILUMYA for psoriatic arthritis
Celularity and Vesalius sign exclusive US peptide manufacturing agreement
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights